Seroprevalence of and coinfection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in the United States were analyzed by use of data from a nationally representative survey (National Health and Nutrition Examination Survey III, 1988 -1994 . Evidence was explored for possible protection by prior HSV-1 infection against infection and clinical disease with HSV-2. Overall, 27.1% of persons aged > 12 years were seronegative for HSV-1 and HSV-2; 51.0% were seropositive for HSV-1 only, 5.3% for HSV-2 only, and 16.6% for both HSV-1 and HSV-2. The seroprevalence of HSV-2 was higher in persons with HSV-1 antibody. Approximately 76% of persons who had HSV-2 antibody also had HSV-1 antibody. Persons seropositive for HSV-2 only reported a history of genital herpes more frequently (16.2%) than persons seropositive for both HSV-1 and HSV-2 (5.9%). The seroprevalence of HSV-1 and age at infection may influence the epidemiology of clinical genital herpes, even if prior HSV-1 infection does not prevent HSV-2 infection.
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are closely related [1] . Infections with HSV-2 typically affect anogenital sites and are transmitted sexually or from a mother's genital infection to the newborn. By contrast, HSV-1 commonly causes orolabial infection. Transmission most frequently occurs via nonsexual routes, although sexual and vertical transmissions also occur. Both viruses are capable of causing either anogenital or orolabial infection and can produce primary and recurrent lesions that are clinically indistinguishable [2] .
In the United States, the number of physician visits for the first episode of genital herpes has been steadily increasing since 1970 [3] . Data from 2 national surveys in the United States during 1976-1980 and 1988-1994 show that, whereas the overall ageadjusted seroprevalence of HSV-2 in persons aged > 12 years increased by 30% between the 2 surveys (from 16.0% to 20.8%) [4] , the overall seroprevalence of HSV-1 was essentially unchanged [5; and J. Schillinger, personal communication] . These data suggest that the United States has experienced an epidemic of herpes due to increasing infection with HSV-2 [6] .
There are conflicting data concerning whether prior infections with HSV-1 or HSV-2 confer protection against acquisition of the other type. Some studies have suggested that prior infection with HSV-1 may provide partial protection against infection with HSV-2 [7] [8] [9] [10] , whereas others have suggested that prior HSV-1 infection has no effect on acquisition of HSV-2 [11, 12] . Data are consistent, however, concerning the effect of prior HSV-1 infection on the expression of disease resulting from HSV-2 infection. Strong evidence indicates that prior HSV-1 infection increases the likelihood that an infection with HSV-2 will be subclinical [7, 12, 13] . Some data also suggest that prior infection with HSV-2 can prevent infection with HSV-1 [11, 14] .
In the present article, we describe the distribution of HSV-1 and HSV-2 in the United States, using data from a nationally representative serologic sample that were collected during the National Health and Nutrition Examination Survey (NHANES) III from 1988 to 1994. We also explore evidence for possible protection by prior HSV-1 infection against infection and clinical disease with HSV-2, by comparing the seroprevalence of HSV-2 infection and the frequency of self-reported clinical genital herpes among individuals with and without HSV-1 infection.
Materials and Methods
Detailed descriptions of sampling and data collection procedures for NHANES III can be found elsewhere [15] . The laboratory methods used to test NHANES serum samples for HSV antibody have also been reported [4] . In brief, serum samples from participants aged > 12 years (n ¼ 13,904) were tested for antibodies to HSV-1 and HSV-2 by use of a type-specific immunodot assay [16, 17] . Purified glycoproteins gG-1 of HSV-1 and gG-2 of HSV-2 were used as antigens for the HSV-1 and HSV-2 assays, respectively. In this analysis, demographic variables were defined according to the recommendations of the National Center for Health Statistics (NCHS) for analysis of NHANES III data [18] . Of note, in NHANES III, race was defined by self-report as "non-Hispanic black," "nonHispanic white (referred to as "black" and "white" in this paper), "Mexican American," or "other." Persons who reported their race in other than the 3 specific categories were classified as "other." On the basis of HSV serology, we classified persons into 4 serostatus groups: seronegative (HSV-1 and HSV-2 negative), HSV-1 only (HSV-1 positive and HSV-2 negative), HSV-2 only (HSV-1 negative and HSV-2 positive), and coinfected (HSV-1 and HSV-2 positive).
SUDAAN software (Release 7.5.2, Research Triangle Institute) was used for statistical analyses because of the complex survey design used in NHANES III. All prevalence estimates were weighted to represent the noninstitutionalized civilian US population by use of weights calculated with an additional poststratification step by NCHS. We considered an estimate of seroprevalence to be unreliable if the SE was > 30% of the seroprevalence estimate, and we did not present such estimates. A logistic regression procedure in SUDAAN (PROC MULTILOG) was used to study the independent association between a given serostatus category and specific demographic or behavioral variables.
Results
Prevalence of HSV infections. Overall, 27.1% of persons aged >12 years in the United States were HSV seronegative (table 1), 51.0% were positive for HSV-1 only, and 5.3% were positive for HSV-2 only; 16.6% of persons were coinfected with HSV-1 and HSV-2.
Significantly more male (31.4%) than female (23.2%) subjects were seronegative for HSV infection (table 1) . Although the seroprevalence of HSV-1 only was similar in male and female subjects, the seroprevalence of coinfection was significantly higher in female than in male subjects. The seroprevalence of HSV-1 only increased with age from 40.0% in 12-19-year-olds to 64.5% in > 70-year-olds. The seroprevalence of HSV-2 only increased from 1.2% in 12-19-year-olds to a peak of 8.5% in 30-39-yearolds. The seroprevalence of coinfection increased with increasing age and then plateaued after age 40 years. HSV seroprevalence also varied by race/ethnicity. Whites were significantly more likely to be seronegative than persons of other race/ethnicity. Mexican Americans had the highest seroprevalence of HSV-1 only. The seroprevalence of both HSV-2 only and coinfection was highest among blacks. Persons who were at or above the poverty index were significantly more likely to be seronegative and less likely to be coinfected than those whose incomes were below the poverty index.
The seroprevalence of coinfection was significantly higher in persons who first had sexual intercourse at a younger age and increased with the total number of lifetime sex partners. The seroprevalence of HSV-2 only showed a similar trend with these 2 behavioral factors. In contrast, the seroprevalence of HSV-1 only did not vary by the age at first sexual intercourse and did not increase with the total number of lifetime sex partners (table 1) .
Effects of HSV-1 on HSV-2 infection. We compared the seroprevalence of HSV-2 in persons with and without HSV-1 antibody. Overall, the seroprevalence of HSV-2 was significantly higher in persons who were seropositive for HSV-1 than in those who were seronegative for HSV-1 (P , :001). The seroprevalence of HSV-2 by HSV-1 serostatus, stratified by age and sex, is shown in figure 1 . In both male and female subjects, HSV-2 seroprevalence appears to be higher in persons seropositive for HSV-1. However, after further adjustment for race/ethnicity using logistic regression models, HSV-2 serostatus was not significantly associated with HSV-1 serostatus (P ¼ :1).
To further evaluate the effect of HSV-1 antibody on HSV-2 infection, we examined the proportion of persons with HSV-2 antibody who were coinfected with HSV-1. Because infections with HSV-1 are more common than infections with HSV-2 at younger ages, persons who are coinfected with HSV-1 and HSV-2 are likely to have acquired HSV-1 infection before HSV-2 infection. In persons who had HSV-2 antibody (total n ¼ 671þ 2861 ¼ 3532; see table 1), 75.9% also had HSV-1 antibody. This percentage was similar in male and female subjects (74.5% in males and 76.8% in females; P . :2).
Reported history of clinical genital herpes. To describe factors associated with clinical genital herpes, we analyzed responses of participants (aged 17-59 years) to the question, "Has a doctor ever told you that you had genital herpes?" Overall, 2.8% of participants reported a history of doctor-diagnosed genital herpes (table 2). The frequency of genital herpes was similar in men and women. Persons infected with HSV-2 only reported a history of genital herpes with significantly higher frequency (16.2%) than persons who were coinfected with HSV-1 and HSV-2 (5.9%). After adjustment for age, sex, and race/ethnicity, persons seropositive for HSV-2 only were~3 times more likely to report a history of genital herpes than those who had antibodies to both HSV-1 and HSV-2 (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.7-5.1).
Predictors for serostatus of HSV-2 only. Compared with persons coinfected with HSV-1 and HSV-2 (n ¼ 2861), persons who were seropositive for HSV-2 only (n ¼ 671) were significantly younger (mean age, 39 vs. 47 years), were more likely to be white (66% vs. 59%), had higher levels of education (45% vs. 27% had an education of . 12 years' duration), had more lifetime sex partners (median, 7 vs. 5), and had an income that placed them above the poverty index (84% vs. 79%; P , :04 for all predictors). However, a person's sex and age at first sexual intercourse were not associated with a serostatus of HSV-2 only or coinfected (P . :3 for both). Using a logistic regression model, we found that persons seropositive for HSV-2 only were more likely to report an age < 39 years (OR, 1.8; 95% CI, 1.4-2.5), white race/ethnicity (OR, 1.6; 95% CI, 1.0-2.5), and education . 12 years (OR, 1.8; 95% CI, 1.3-2.4), when compared with persons coinfected with HSV-1 and HSV-2. The number of lifetime sex partners and income below or above the poverty index were not signifi-cantly associated with being seropositive for HSV-2 only, after adjustment for other variables in the model (P . :1).
Discussion
This analysis, which used nationally representative data, shows that~73% of the population aged >12 years in the United States had antibodies to 1 or both types of HSV. These data also suggest that prior HSV-1 infection reduces the likelihood that an infection with HSV-2 is symptomatic, but it may not protect against acquisition of HSV-2 infection.
Because of the cross-sectional nature of NHANES III, we cannot separate a cohort effect from the effect of age. The seroprevalence of HSV-2 only and that of coinfection peaked before age 40 years. Possible explanations for this include worsening of the HSV-2 epidemic in the United States in recent decades and a decreased likelihood for a person to acquire new HSV-2 infection after age 40 years. The seroprevalence of HSV-1 increased with increasing age, which suggests that many persons may acquire HSV-1 in adulthood or that earlier birth cohorts had a higher incidence of HSV-1 infection than did later cohorts.
These data from NHANES III support other studies indicating that prior HSV-1 infection may not protect against acquisition of HSV-2. Admittedly, NHANES III is not ideal to study the interaction between HSV-1 and HSV-2, because the data are cross-sectional. However, because most people probably acquire HSV-1 earlier in life than HSV-2, we reason that, if prior HSV-1 infection had strongly protected against acquisition of HSV-2, HSV-2 seroprevalence would be lower in persons with HSV-1 antibody than in those without HSV-1 antibody, and co- infection with both HSV-1 and HSV-2 would be uncommon. To the contrary, we found that the seroprevalence of HSV-2 was higher among persons who had HSV-1 antibody than among those without HSV-1 antibody, and~76% of persons who had HSV-2 antibody also had HSV-1 antibody.
Our study also found that neither the patterns of HSV-2 seroprevalence by HSV-1 serostatus nor the relative percentage of persons with HSV-2 antibody who were coinfected with HSV-1 differs by sex. Several studies, however, have suggested that prior HSV-1 infection may provide partial protection against acquisition of HSV-2 infection, although the protective effect may be limited to women. A prospective study by Mertz et al. [8] found that preexisting HSV-1 antibody was associated with a reduced risk of acquisition of HSV-2 infection in women, but that was a relatively small study based on a total of 11 HSV-2 seroconversions in women. In men, there were only 3 HSV-2 seroconversions, and no conclusions could be made. A protective effect conferred by prior HSV-1 infection in women was also suggested in a smaller prospective study by Bryson et al. [9] and in a cross-sectional study [7] . In contrast, a prospective study by Brown et al. [11] found that the acquisition rate of HSV-2 was similar in pregnant women with and without prior HSV-1 infection. To date, the best data concerning the possible protective effect of HSV-1 antibody on acquisition of HSV-2 infection are from a clinical trial [12] in which 1508 persons seropositive for HSV-1 and 885 persons seronegative for HSV-1 were followed prospectively. Similar to what we found in this analysis, the researchers of that clinical trial concluded that HSV-1 antibody had no effect on the rate of acquiring HSV-2 infection (the HSV-2 seroconversion rate was 5.1 vs. 5.2 per 100 person-years in those who did and did not have preexisting HSV-1 antibody).
In a cross-sectional study such as ours, the ability to detect potential protection of HSV-1 infection against HSV-2 may be limited; persons with HSV-1 infection may be more likely to be exposed to HSV-2, because the 2 viruses share some common social and behavioral risk factors and a common mode of sexual transmission. Although the NHANES III data are not ideal to evaluate the possibility that prior HSV-1 infection may be partially protective against HSV-2, findings from our analysis suggest that such protection, if any exists, may not be strong enough to be evident in either men or women at the population level.
Our data support observations that prior HSV-1 infection alters the clinical manifestations of HSV-2 infection. Persons seropositive for HSV-2 only were 3 times more likely to have a history of clinical genital herpes than those coinfected with HSV-1 and HSV-2. This finding is consistent with several previous studies. Langenberg et al. [12] found that, when HSV-2 infection was newly acquired, persons who had no HSV-1 antibody were more likely to be symptomatic than those who were NOTE. Only persons who had ever had sex were asked the question about the history of genital herpes;~92% of eligible persons answered the question in NHANES III. CI, confidence interval; HSV, herpes simplex virus.
a Serum samples were available for 8469 persons who had answered the question about history of genital herpes; the distribution according to age, sex, and race was similar among those whose HSV serostatus was or was not available.
seropositive for HSV-1. Similarly, Koutsky et al. [13] found that persons with HSV-2 only were 2.4 times more likely to have recognized prior episodes of genital infection than those who had both HSV-1 and HSV-2 antibodies. Taken together with our population-based data, these studies indicate that persons infected with HSV-2 only, although accounting for only about one-fourth of those infected with HSV-2 in the United States, may have a disproportionate amount of the morbidity from HSV and may contribute substantially to the medical cost associated with genital herpes.
Our finding that persons seropositive for HSV-2 only were significantly younger than those coinfected has several possible explanations. One is that prior HSV-1 infection is partially protective and delays acquisition of HSV-2. A second explanation is that, if prior HSV-2 infection prevents HSV-1 infection, as was suggested by some early studies [11, 14] , the higher percentage of HSV-2 only in young persons could indicate that the later birth cohorts acquired HSV-2 infection at younger ages, before acquiring HSV-1 infection. In NHANES III, the percentage of persons who had their first sexual intercourse at age <17 years was 64% in 20-29-year-olds, in comparison with only 44% in 50-59-year-olds.
The age at which a person acquires HSV-1 and HSV-2 infections has important implications for the epidemiology of genital herpes. First, because persons who lack HSV-1 antibody are more likely to have symptomatic HSV-2 infection, acquisition of HSV-2 before HSV-1 would lead to an increase in clinical genital herpes. Second, if fewer persons acquire HSV-1 infection in childhood, genital herpes due to HSV-1 infection may increase, especially if oral sex becomes more common [19, 20] . A prospective study during the 1990s reported that, among sexually active adults, new symptomatic genital HSV-1 infections are as common as new symptomatic oropharyngeal HSV-1 infections, at a rate of 0.5 cases per 100 person-years [12] . Recently, a large study of the etiology of genital herpes found that the proportion of primary genital herpes infections due to HSV-1 was 15% among heterosexual men, 21% among heterosexual women, and 47% among homosexual men [21] .
Because genital herpes can facilitate human immunodeficiency virus transmission [22] , understanding the epidemiology of HSV infections and the factors that affect their clinical manifestations is of critical importance. The seroprevalence of HSV-1 and the age at its acquisition may influence the epidemiology of clinical genital herpes in the United States. Furthermore, if the efficacy of HSV-2 vaccines that are currently under development [23] differs by HSV-1 serostatus, monitoring the seroprevalence of both HSV-1 and HSV-2 will be important for development of preventive and vaccination strategies.
